Mode
Text Size
Log in / Sign up

Liquid biopsy shows high sequencing success in high-risk localized prostate cancer feasibility studyBlood Tests Replace Biopsies for Prostate Cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider liquid biopsy feasibility data preliminary; concordance with tissue requires larger validation.

This phase 2 neoadjuvant trial evaluated the feasibility and performance of liquid-based genomic profiling (using cell-free DNA from plasma) compared to tissue-based genomic profiling (using FFPE tissue) in patients with high-risk localized prostate cancer. The study analyzed 22 FFPE tissue biopsies and 27 plasma samples, with sequencing success rates, coverage and depth, and detection of low-frequency mutations as secondary outcomes.

Only 12 of 22 FFPE tissue biopsies (54.5%) yielded usable data, while all 27 plasma samples (100%) were successfully sequenced. Liquid-based profiling detected an average of 3.5 genomic variants per sample, suggesting detection of biologically relevant alterations. Concordance analysis between the two methods was limited to just 4 matched samples, preventing meaningful comparison.

Safety and tolerability data were not reported. Key limitations include low circulating tumor DNA levels typical in localized disease, low DNA quality or quantity in many FFPE tissue biopsies, and the very small number of matched samples available for concordance analysis. Funding and conflicts of interest were not reported.

While liquid biopsy demonstrated robust technical performance in this small feasibility study, its practice relevance remains preliminary. The findings suggest plasma-based profiling could serve as a complementary approach when tissue samples are limited or of suboptimal quality. However, larger studies are required to establish concordance with tissue profiling and determine clinical utility in treatment decision-making for high-risk localized prostate cancer.

Imagine having a serious health scare but fearing a painful needle stick in your prostate. Now, imagine getting the same vital information from a simple blood draw instead.

The Big Shift in Testing

Men with high-risk localized prostate cancer often face a tough choice. Doctors usually need a tissue biopsy to check for dangerous gene changes. This procedure can be uncomfortable and sometimes fails to give a clear answer.

But there is a new option. Scientists are finding that a simple blood test can do the job just as well. This method looks for tiny bits of DNA floating in your blood.

Prostate cancer is common, but finding the right treatment is hard. Many men have tumors that are hard to reach with a needle. When doctors try to get a tissue sample, they often get too little DNA to work with.

This leaves a gap in care. Patients might miss out on knowing exactly what their cancer looks like at the genetic level. Without this info, doctors cannot pick the best drugs to stop the disease early.

The Surprising Twist

For years, doctors believed tissue was the only way to go. They thought blood tests just couldn't find enough DNA in early-stage cancer.

But here is the twist. A new study shows blood tests work perfectly even when the cancer is still inside the prostate. The blood test found DNA in every single sample tested.

Think of your DNA like a unique fingerprint. When cells die, they drop pieces of this fingerprint into your blood. These are called cell-free DNA.

In the past, these pieces were too small to see in early cancer. Now, new machines can spot them like a lighthouse spotting a ship in the fog. The test acts like a super-powered filter that catches these tiny signals.

Researchers looked at 22 men with high-risk prostate cancer. They compared two methods: taking a tissue sample and taking a blood sample.

They used special tools to read the DNA in both types of samples. The goal was to see which method worked better and found more useful information.

The results were clear. The tissue method failed to work in more than half the cases. Low-quality DNA made it impossible to read the sample in many men.

The blood method succeeded every single time. All 27 blood samples gave usable results. The test found the same gene changes in both methods when they could be compared.

The Catch

This doesn't mean this treatment is available yet.

While the blood test works well, it is still in the research phase. Scientists need to prove it works for every type of patient. They also need to show it helps men live longer or feel better.

If you have prostate cancer, talk to your doctor about testing options. A blood test might be easier if a tissue biopsy is risky or hard to do.

However, do not stop your current treatment plan. Ask your doctor if a blood test can add useful information to your care plan. It could help choose the right medicine sooner.

More studies are needed to confirm these results. Scientists will test this method on larger groups of people. They will also check if it works for different types of prostate cancer.

Until then, this new tool is a helper, not a replacement. It gives doctors another way to look at the disease. This could lead to better care for men in the future.

Study Details

Study typePhase2
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundTumor genomic profiling using liquid biopsies offers a minimally invasive alternative to tissue biopsy-based approach, with advantages in accessibility, tumor heterogeneity representation, and repeatability. While established in metastatic prostate cancer, its feasibility in localized disease remains unclear due to low ctDNA levels.MethodsWe evaluated the feasibility and performance of tissue and liquid-based genomic profiling in patients with high-risk localized prostate cancer enrolled in a phase 2 neoadjuvant trial. Genomic DNA from formalin-fixed paraffin-embedded (FFPE) tissue and cell-free DNA from plasma were analyzed using Illumina TruSight Oncology 500 panels and DRAGEN™ pipelines, with in-house filtering of artifacts and germline variants.ResultsOf 22 FFPE tissue biopsies, only 54.5% (12/22) yielded usable data, with failures due to low DNA quality or quantity. All 27 plasma samples (100%) were successfully sequenced, despite low ctDNA levels. Both approaches identified an average of 3.5 genomic variants per sample, including alterations in SPOP, ATRX, ATM, and ARID1B. Liquid-based genomic profiling achieved superior coverage and depth, enabling sensitive detection of low-frequency mutations. Concordance analysis was limited by the small number of matched samples (n = 4).ConclusionsLiquid-based genomic profiling is feasible and achieved high sequencing success rates in high-risk localized prostate cancer. Although concordance analysis was limited, plasma-based profiling showed robust sequencing performance and detected biologically relevant alterations. These findings support liquid biopsy as a complementary approach for molecular characterization, particularly when tissue samples are limited or of suboptimal quality. Larger studies are required to establish concordance and clinical utility.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.